These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 30407325)
1. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report. Li M; Mou Y; Hou S; Cao D; Li A Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325 [TBL] [Abstract][Full Text] [Related]
2. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review. Matsubayashi H; Todaka A; Tsushima T; Kiyozumi Y; Harada R; Ishihara E; Higashigawa S; Ohike N; Sakamoto H; Sato J; Ishiwatari H; Sugiura T; Uesaka K Fam Cancer; 2024 Aug; 23(3):393-398. PubMed ID: 38733420 [TBL] [Abstract][Full Text] [Related]
3. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation. Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767 [TBL] [Abstract][Full Text] [Related]
4. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693 [TBL] [Abstract][Full Text] [Related]
5. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report. Wu C; Fan M; Hu Y Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603 [TBL] [Abstract][Full Text] [Related]
6. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study. Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389 [TBL] [Abstract][Full Text] [Related]
7. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A Cells; 2020 Sep; 9(9):. PubMed ID: 32948057 [TBL] [Abstract][Full Text] [Related]
8. Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival. Kubo T; Ikeda Y; Muramatu J; Ishikawa K; Yoshida M; Kukita K; Imamura M; Sugita S; Sakurai A; Takada K Cancer Rep (Hoboken); 2024 Aug; 7(8):e70007. PubMed ID: 39188100 [TBL] [Abstract][Full Text] [Related]
9. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382 [TBL] [Abstract][Full Text] [Related]
10. Maintenance Olaparib for Germline Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963 [TBL] [Abstract][Full Text] [Related]
11. A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection. Watanabe T; Nagaoka Y; Kimura N; Fukasawa M; Shirai Y; Hirano K; Shibuya K; Yoshioka I; Hamashima T; Fujii T Clin J Gastroenterol; 2024 Oct; 17(5):970-975. PubMed ID: 38836973 [TBL] [Abstract][Full Text] [Related]
12. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685 [TBL] [Abstract][Full Text] [Related]
13. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085 [TBL] [Abstract][Full Text] [Related]
14. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. Munroe M; Kolesar J Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701 [TBL] [Abstract][Full Text] [Related]
15. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature. Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108 [TBL] [Abstract][Full Text] [Related]
17. A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report. Wang D; Guan R; Tao Q; Liu S; Yu M; Li X BMC Med Genomics; 2021 Jan; 14(1):6. PubMed ID: 33407459 [TBL] [Abstract][Full Text] [Related]
18. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000 [TBL] [Abstract][Full Text] [Related]
19. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916 [TBL] [Abstract][Full Text] [Related]
20. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]